REPLIGEN CORP

REPLIGEN CORP (RGEN) is a publicly listed company on US equity markets.

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

The company reports trailing twelve-month revenue of $44.83M and net income of $8.33M.

Key metrics include a return on equity of 0.4%, a debt-to-equity ratio of 0.39.

Use FINOTAUR to track RGEN's price action, review fundamentals, and stay current with company news — all in one research dashboard.